Mirati Therapeutics, Inc. (NASDAQ:MRTX) Q1 2023 Earnings Call Transcript

Operator: Good afternoon, and welcome to the Mirati Therapeutics First Quarter 2023 Earnings Call. My name is Justin, and I will be the operator for today’s call.

Related Keywords

United States ,America ,Tyler Van Buren ,Jamie Christensen ,Evan Seigerman ,Jay Olson ,Chuck Baum ,Jason Gerberry ,Ben Hickey ,Silvan Tuerkcan ,Salveen Richter ,Kalpit Patel ,Laurie Stelzer ,Andy Fleszar ,Deric Joseph ,Ben Burnett ,Maury Raycroft ,Alan Sandler ,Bryan Asay ,Jonathan Miller ,Gena Wang ,Yigal Nochomovitz ,Michael Schmidt ,Corporate Affairs At Mirati ,Head Of Research ,European Medicines Agency ,National Comprehensive Center Network ,Nasdaq ,Morgan Stanley ,Pfizer ,Mirati Therapeutics Inc ,Barclays ,Exchange Commission ,Goldman Sachs ,Mirati Therapeutics ,Call Transcript May ,Mirati Therapeutics First Quarter ,Vice President ,Corporate Affairs ,David Meek ,Chief Executive Officer ,Chief Medical Officer ,Chief Scientific Officer ,Chief Commercial Officer ,Chief Financial ,New Drug Application ,New England Journal ,Breakthrough Therapy Designation ,Plenary Series ,Van Buren ,Mike Ulz ,Dana Farber Cancer Institute ,Memorial Sloan Kettering ,Tango Therapeutics ,Ami Fadia ,